IL6 and posterior cortical atrophy: Additionally, in studies evaluating combination therapies for PCa BoM, ruxolitinib, effectively inhibited the IL-6/JAK/STAT3 signaling pathway in IL-6-driven models, thereby restoring sensitivity to anti-hormone therapy.